Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4424183 | 0.98 | PLAU (0.41) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL11203540 | 0.85 | PLAU (0.42) | PLAUMAPTNFKB1THPOHIF1A | |
| Hydrochloric Acid SCHEMBL11203468 | 0.83 | PLAU (0.41) | PLAUMAPTNFKB1THPOHIF1A | |
| SCHEMBL12432084 | 0.78 | PDK1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL14385913 | 0.78 | PDK1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL4429376 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL4419711 | 0.75 | — | — | |
| SCHEMBL21724465 | 0.74 | SIRT1 (0.35) | — | |
| SCHEMBL11209001 | 0.73 | DRD2 (0.45) | DRD2DRD3 | |
| SCHEMBL12431974 | 0.73 | MAPT (0.38) | MAPTHSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0013789-B1 | AMINO-SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H (OR 2H)-INDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1983-02-02 | — | — | EP | claimed |
| US-4276300-A | PROLACTIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1981-06-30 | — | — | US | claimed |
| EP-0013789-A1 | Amino-substituted 4,5,6,7-tetrahydro-1H (or 2H)-indazoles, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | claimed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013058258-A1 | BICYCLIC HETEROCYCLIC COMPOUND | アステラス製薬株式会社 (JP) | 2013-04-25 | — | — | WO | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
| EP-0013789-B1 | AMINO-SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H (OR 2H)-INDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1983-02-02 | — | — | EP | disclosed |
| US-4322540-A | PROLACTIN INHIBITOR | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4322430-A | Amino-substituted 4,5,6,7-tetrahydro-1H (or 2H)-indazoles | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4276300-A | PROLACTIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0013789-A1 | Amino-substituted 4,5,6,7-tetrahydro-1H (or 2H)-indazoles, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | PLAU 3954/4885MAPT 2494/4885NFKB1 2478/4885 |
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | PLAU 64/4885MAPT 3554/4885NFKB1 1410/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | PLAU 4611/4885MAPT 1307/4885NFKB1 1247/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | PLAU 4308/4885MAPT 2629/4885NFKB1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.